The pause in JNJ vaccinations is purely political. We have enough doses of Pfizer and Moderna to vaccinate the population that wants to be vaccinated. Supply now outstrips demand in many parts of the country. Administration doesn't want to risk any blowback for blood clots when there are sufficient stockpiles of other vaccines.
So, precautionary pause on JNJ doesn't affect vaccine rollout, which is currently being affected more by vaccine hesitancy than other factors. The pause also signals caution, and hopefully steers some of the vaccine hesitant to get Pfizer or Moderna shots.
In all likelihood, just as with the AZ vaccine in Europe, guidelines will come out that JNJ should be reserved for 50+, 65+, or some other population group. We will then quietly "loan" our JNJ vaccine stockpile to other countries as part of vaccine diplomacy, as we did with AstraZeneca.
So, precautionary pause on JNJ doesn't affect vaccine rollout, which is currently being affected more by vaccine hesitancy than other factors. The pause also signals caution, and hopefully steers some of the vaccine hesitant to get Pfizer or Moderna shots.
In all likelihood, just as with the AZ vaccine in Europe, guidelines will come out that JNJ should be reserved for 50+, 65+, or some other population group. We will then quietly "loan" our JNJ vaccine stockpile to other countries as part of vaccine diplomacy, as we did with AstraZeneca.